BACE1, also known as β-secretase 1, is a potential drug target for the treatment of Alzheimer’s disease (AD) due to its involvement in the abnormal production of β-amyloid plaques in AD patients [110,111]. Here, BACE1 is linked to early-onset autosomal dominant Alzheimer disease.